Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Determining the effects of risperidal Consta in patients with psychotic disorders and incomplete adherence.

Next Previous
Trial Profile

Determining the effects of risperidal Consta in patients with psychotic disorders and incomplete adherence.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use

Most Recent Events

  • 01 Mar 2012 Actual patient number (64) added as reported by ClinicalTrials.gov.
  • 01 Mar 2012 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
  • 25 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top